Neurological Disease

(Rac)-Rotigotine-d₇ (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

hMAO-B-IN-3 (Compound 15) is a potent inhibitor of hMAO-B with an IC₅₀ of 47.4 nM. hMAO-B-IN-3 is playing favourable agent-like properties and a broad safety window. hMAO-B-IN-3 is thus a suitable candidate for lead optimization and the development of multitarget-directed ligands.

Sultopride (LIN-1418) is a selective antagonist of dopamine D2 receptor.

PF-05150122 is a novel potent and selective human Nav1.7 channel blocker with the activity of inhibiting human pain signaling. PF-05150122 exhibited favorable biopharmacokinetic parameters in microdose studies, providing a basis for exploring its application in acute or chronic pain inhibition. The pharmacokinetic model of PF-05150122 predicted that at the corresponding oral dose, it could effectively reduce the 50% inhibitory concentration (IC50) of Nav1.7, demonstrating its inhibitory potential.

[1,6-Aminosuberic acid]-arginine-Vasotocin is a synthetic peptide analogue to neurohypophyseaI hormones. [1,6-Aminosuberic acid]-arginine-Vasotocin has excitatory effect on the periodically oxcillating neuron (PON) of A. fulica.

LRRK2-IN-19 is a PROTAC target protein ligand that can be used to synthesize PROTAC JH-XII-03-02 (HY-155150). JH-XII-03-02 is a highly potent and selective LRRK2 PROTAC degrader, which can be used in Parkinson's disease research.

RIPK1-IN-33 is a blood-brain barrier-permeable and orally active RIPK1 inhibitor, with an IC₅₀ of 0.115 μM. RIPK1-IN-33 demonstrates remarkable anti-ferroptosis activity, radical scavenging capacity (IC₅₀ = 123.3 μM), and anti-lipid peroxidation effects (IC₅₀ = 9.72 μM). RIPK1-IN-33 markedly reduces cerebral infarction volume and improves neurological function scores in transient middle cerebral artery occlusion (tMCAO) model. RIPK1-IN-33 can be used for the study of ischemic stroke.

Tirilazad (U 74006F free base) Standard is the analytical standard of Tirilazad (HY-132280). This product is intended for research and analytical applications. Tirilazad (U 74006F free base) is a neuroprotective agent. Tirilazad can also bind tightly to the main protease of the COVID-19 virus and exert anti-SARS-CoV-2 activity. Tirilazad scavenges hydroxyl and lipid peroxyl free radicals and maintains the levels of endogenous antioxidants. Tirilazad reduces cerebral infarct volume and improves neurobehavioral scores in animal models of focal ischemia. Tirilazad can be used in research related to ischemic stroke and subarachnoid hemorrhage.

(E/Z)-Ensifentrine is a dual inhibitor of PDE3/4. (E/Z)-Ensifentrine reduces the inflammatory cells into the airways. (E/Z)-Ensifentrine has bronchodilatory and anti-inflammatory activities in vitro and in vivo model.

SR10098 is a benzimidazole-based Nurr1 activator with an EC₅₀ of 24 nM against full-length Nurr1. SR10098 does not directly bind to the ligand-binding domain of Nurr1, regulates transcription via a Nurr1-independent pathway, and exhibits no significant cytotoxicity. SR10098 can be used in studies of Nurr1-related diseases, such as Alzheimer's disease and Parkinson's disease.

Cerlapirdine hydrochloride is a selective and potent full antagonist of the 5-hydroxytryptamine 6 (5-HT6) receptor. Cerlapirdine hydrochloride has the potential for researching the Alzheimer's disease.

Casein kinase 1δ-IN-20 (compound 427) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-20 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.

Mezilamine is a potent antidopaminergic agent. Mezilamine induces a concentration dependent increase in the electrically stimulated overflow of ³H-noradrenaline from rat cortical slices, without affecting the basal overflow. Mezilamine acts as a presynaptic α-adrenoceptor antagonist and a postsynaptic α-adrenoceptor agonist.

cis-Indatraline (cis-Lu 19-005) hydrochloride is an active compound. cis-Indatraline (cis-Lu 19-005) hydrochloride can be used for the research of neurodegenerative diseases.

hTrkA-IN-2 is a selective hTrkA allosteric inhibitor with an IC₅₀ value of 3.9 nM.

PD 119819 is a highly selective benzopyran-4-one brain dopamine autoreceptor agonist. PD 119819, a heterocyclic piperazine, inhibits spontaneous locomotor activity and brain dopamine synthesis.

L-Aspartic acid potassium (Standard) is the analytical standard of L-Aspartic acid potassium (HY-N0666A). This product is intended for research and analytical applications. L-Aspartic acid potassium (potassium L-aspartate) is a NMDA receptor agonist and acidic amino acid. L-Aspartic acid potassium has no independent analgesic activity. L-Aspartic acid potassium can antagonize the analgesic effects of D-Aspartic acid and Morphine. L-Aspartic acid potassium regulates polymorph transformation, crystal growth/aggregation and nucleation processes of calcium carbonate, and can serve as a biomineralization template. L-Aspartic acid potassium promotes burst firing of central neurons. L-Aspartic acid potassium can be used in studies related to cerebral ischemia and epilepsy.

ARN25699 is a kinase inhibitor with an IC₅₀ of 5.5 nM against GSK-3β, 2.2 nM against FYN-α, and 242.3 nM against DYRK1A, and it exhibits oral bioavailability. ARN25699 reduces hyperphosphorylation of tau protein and promotes microtubule bundle formation. ARN25699 has a broader kinome inhibitory profile and targets kinases associated with the pathogenic mechanisms linked to Alzheimer's disease. ARN25699 can be used in the research of Alzheimer's disease and related tauopathies.

3-Methoxytyramine-d₃ hydrochloride (3-O-methyl Dopamine-d₃ hydrochloride) is the deuterium labeled 3-Methoxytyramine hydrochloride (HY-103638). 3-Methoxytyramine hydrochloride is an inactive metabolite of dopamine which can activate trace amine associated receptor 1 (TAAR1).

Mirodenafil-d₇ (SK3530-d₇) is the deuterium labeled Mirodenafil (HY-14930). Mirodenafil (SK3530) is an orally active, potent, reversible, and selective?phosphodiesterase?5 (PDE5)?inhibitor. Mirodenafil is a?glucocorticoid receptor?(GR)?modulator Mirodenafil activates the?Wnt/β-catenin?signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc).